GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » MedTech Acquisition Corp (NAS:MTACU) » Definitions » Debt-to-EBITDA

MedTech Acquisition (MedTech Acquisition) Debt-to-EBITDA : -0.58 (As of Jun. 2023)


View and export this data going back to 2020. Start your Free Trial

What is MedTech Acquisition Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

MedTech Acquisition's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $3.33 Mil. MedTech Acquisition's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $0.00 Mil. MedTech Acquisition's annualized EBITDA for the quarter that ended in Jun. 2023 was $-5.72 Mil. MedTech Acquisition's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2023 was -0.58.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for MedTech Acquisition's Debt-to-EBITDA or its related term are showing as below:

MTACU' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.85   Med: -0.6   Max: -0.36
Current: -0.82

During the past 3 years, the highest Debt-to-EBITDA Ratio of MedTech Acquisition was -0.36. The lowest was -0.85. And the median was -0.60.

MTACU's Debt-to-EBITDA is not ranked
in the Diversified Financial Services industry.
Industry Median: 5.42 vs MTACU: -0.82

MedTech Acquisition Debt-to-EBITDA Historical Data

The historical data trend for MedTech Acquisition's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedTech Acquisition Debt-to-EBITDA Chart

MedTech Acquisition Annual Data
Trend Dec20 Dec21 Dec22
Debt-to-EBITDA
N/A -0.36 -0.85

MedTech Acquisition Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.25 -0.95 -0.43 -0.89 -0.58

Competitive Comparison of MedTech Acquisition's Debt-to-EBITDA

For the Shell Companies subindustry, MedTech Acquisition's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MedTech Acquisition's Debt-to-EBITDA Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, MedTech Acquisition's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where MedTech Acquisition's Debt-to-EBITDA falls into.



MedTech Acquisition Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

MedTech Acquisition's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.983 + 1.341) / -2.746
=-0.85

MedTech Acquisition's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(3.331 + 0) / -5.72
=-0.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2023) EBITDA data.


MedTech Acquisition  (NAS:MTACU) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


MedTech Acquisition Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of MedTech Acquisition's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


MedTech Acquisition (MedTech Acquisition) Business Description

Traded in Other Exchanges
N/A
Address
48 Maple Avenue, Greenwich, CT, USA, 06830
Website
MedTech Acquisition Corp is a blank check company.
Executives
Magnetar Financial Llc 10 percent owner 1603 ORRINGTON AVE., 13TH FLOOR, EVANSTON IL 60201
Magnetar Capital Partners Lp 10 percent owner 1603 ORRINGTON AVE., 13TH FLOOR, EVANSTON IL 60201
Supernova Management Llc 10 percent owner 1603 ORRINGTON AVENUE, 13TH FLOOR, EVANSTON IL 60201
David J. Snyderman 10 percent owner C/O MAGNETAR FINANCIAL LLC, 1603 ORRINGTON AVENUE, 13TH FLOOR, EVANSTON IL 60201
David L Treadwell director 222 S 15TH STREET, SUITE 600 N, OMAHA NE 68102
Manuel Aguero director 600 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10022
Thierry B. Thaure director 3957 POINT EDEN WAY, HAYWARD CA 94545
David J Matlin director, 10 percent owner, officer: Chief Financial Officer
Karim Karti director C/O IRHYTHM TECHNOLOGIES, INC., 650 TOWNSEND STREET, SUITE 500, SAN FRANCISCO CA 94103
Christopher C Dewey director, 10 percent owner, officer: Chief Executive Officer 120 BROADWAY, 27TH FLOOR, NEW YORK NY 10271
Robert H. Weiss officer: Chief Admin Officer and Sec. 585 WEED STREET, NEW CANAAN CT 06840
Maurice R Ferre director C/O MAKO SURGICAL CORP., 2555 DAVIE ROAD, FORT LAUDERDALE FL 33317
Ivan Delevic director C/O MAKO SURGICAL CORP., 2555 DAVIE ROAD, SUITE 110, FORT LAUDERDALE FL 33317
Medtech Acquisition Sponsor Llc 10 percent owner 1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105
Martin William Roche director 600 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10022

MedTech Acquisition (MedTech Acquisition) Headlines

From GuruFocus